Q3 2025 Earnings Call Transcript November 4, 2025 Verastem, Inc. misses on earnings expectations. Reported EPS is $-1.35 EPS, ...
A live webcast of the fireside chats can be accessed under “Events & Presentations” in the Investor section of the Company’s website, https://investor.verastem.com/events. A replay of the webcasts ...
New research from Moffitt Cancer Center shows that RAS(ON) multi-selective inhibition can directly block tumor growth and ...
Parkinson's and Alzheimer's diseases are the two most common neurodegenerative disorders, affecting millions of people ...
New research from Moffitt Cancer Center shows that RAS(ON) multi-selective inhibition can directly block tumor growth and ...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported ...
New case studies on first-line pancreatic cancer patients treated with atebimetinib in combination with FOLFIRINOX to be shared by trial ...
Joshua K. Sabari, MD, director of High Reliability Organization Initiatives at NYU Langone Health's Perlmutter Cancer Center, ...